Compugen Says First Patient Dosed in Phase 1 Trial of COM503
Compugen Announced That The First Patient Was Dosed In A Phase 1 Clinical Trial With Com503, A Potential First-in-class Antibody Against Il-18 Binding Protein Licensed By Compugen To Gilead
The Past Five Years for Compugen (NASDAQ:CGEN) Investors Has Not Been Profitable
Compugen Announces USPTO Grants New Patent for Use of COM902
Express News | Compugen Expands Its Intellectual Property Portfolio With New U.S. Patent Covering Triple Combination Use of Com902 (Reduced Fc Anti-Tigit) With Anti-Pd-1 and Anti-Pvrig Antibodies
Roche Anti-TIGIT Therapy Fails to Extend Survival in Late-stage Lung Cancer Trial
Ezkilz : no news is moving any share?
Jaguar8 OP Ezkilz : It’s a red day because of the Fed report
Ezkilz Jaguar8 OP : ok i got some jspr, how do i check cash on hand?
Jaguar8 OP Ezkilz : Dilution tracker